PNC Financial Services Group Inc. Acquires 12,166 Shares of Gilead Sciences, Inc. $GILD

PNC Financial Services Group Inc. boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the 1st quarter, Holdings Channel reports. The firm owned 486,271 shares of the biopharmaceutical company’s stock after acquiring an additional 12,166 shares during the period. PNC Financial Services Group Inc.’s holdings in Gilead Sciences were worth $67,772,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Strategic Investment Solutions Inc. IL purchased a new stake in Gilead Sciences during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC boosted its stake in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $26,000. Wealth Preservation Advisors LLC increased its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Wilkerson Advisory Group LLC increased its stake in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 78 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.4%

GILD stock opened at $130.86 on Friday. The stock has a 50-day simple moving average of $129.55 and a two-hundred day simple moving average of $135.54. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The firm has a market capitalization of $162.47 billion, a PE ratio of 17.83 and a beta of 0.32. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 29th. Stockholders of record on Monday, June 15th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is presently 44.69%.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $126.29, for a total value of $1,894,350.00. Following the sale, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at $76,674,826.57. This trade represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 77,000 shares of company stock worth $9,978,740. Insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Morgan Stanley dropped their price objective on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Truist Financial cut their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating for the company in a research note on Tuesday, July 7th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective on the stock in a research note on Wednesday, May 20th. Finally, Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $158.33.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.